Navigation Links
Legislative and Regulatory Outlook - 2009 and Beyond for Pharma, Biotech Players
Date:2/13/2008

NEW YORK, Feb. 13 /PRNewswire/ -- Today, more than ever before, pharmaceutical sales and marketing executives are facing challenges from all sides. Internally, the pressure to fill pipelines, demands for more R&D results, and competition from generics demand new outcomes from pharmaceutical marketing and sales teams across the board.

Externally, new U.S.-based regulatory (e.g. post-approval monitoring), legislative, and patent issues continue to loom. Changes affecting the sales and marketing functions of the industry are inevitable as a new administration takes control of the FDA, FTC and other agencies in 2009.

International Institute for Business Information & Growth (iiBIG) presents the 2nd Annual Pharmaceutical Sales & Marketing Executive Congress, scheduled for March 31 - April 1, 2008 in Bethesda, Maryland. This year's conference will outline trends, case studies, and best-practices required to reformulate pharmaceutical marketing and sales strategies in the light of the new rules of engagement. Two new speakers to join our speaking faculty are:

-- Adriane Fugh-Berman MD, Associate Professor, Complementary and

Alternative Medicine Masters Program, Department of Physiology and

Biophysics, Georgetown University

Dr. Fugh-Berman will discuss important developments from the physician side and how physicians are responding to some irregular and wrong practices in pharma CME.

-- Lori Ryan, Executive Director, Head of Finance CVM Sales Force,

Novartis Pharmaceuticals

Ms. Ryan joins our panel on the State of the Industry - Challenges & Opportunities in 2008 and Beyond, joining distinguished faculty from Best Practices, Jazz Pharmaceuticals, and Scientific Advantage.

Dr. Fugh-Berman and Ms. Ryan joins top industry leaders in this field including Hon. Gene Green (D-TX), Member, Health Subcommittee - Energy & Commerce Committee, U. S. House of Representatives; Paul J. Savidge, VP, Global Labeling & Compliance, Bristol-Myers Squibb; Liliana A. Gil, Worldwide Director of Marketing Services & Hispanic Strategy Lead, Johnson & Johnson; and Ellen Shapiro, Director, Division of Communications, Center for Drug Evaluation and Research (CDER), FDA.

This year's agenda will review the latest developments - legislative and otherwise - from Capitol Hill to burgeoning competition to missed opportunities affecting Big Pharma's marketing, sales, and compliance efforts for market dominance.

For Conference Updates and Speaker Roster: http://www.iibig.com/P0802.


'/>"/>
SOURCE iiBIG
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Healing Our Land, Inc. and The Massachusetts Black Legislative Caucus Convene Prevention Is Power Community Forum on the Impact of HIV/AIDS on Communities of Color in Massachusetts
2. MichBio Announces Formation of Biotechnology Legislative Caucus
3. Hospital-led Coalition Cautions Motorists on New Risks October 1, Lauds Legislative Leaders for Scheduling No-fault Hearings Next Week
4. University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix
5. AHCA: Rescinding $2.7 Billion Medicare Cuts Top Issue for Fall Legislative Agenda
6. Cipher provides CIP-TRAMADOL ER regulatory update
7. Mybank Goes Live With Misys Equation to Support Rapid Growth and Meet Future Regulatory Requirements
8. Mannatech Names New VP of Regulatory Affairs, Quality Assurance
9. Cardiome And Astellas Announce Regulatory Update
10. CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
11. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology: